GSK vs Novo Nordisk A S
GSK and Novo Nordisk A S are similar in size: $43.09bn and $46.82bn of revenue in their latest fiscal years. Novo Nordisk A S grew faster (11.1% against 7.5%). Novo Nordisk A S kept more of each dollar of sales as profit: a net margin of 33.1% against 17.5%. GSK carries less debt relative to equity (108.2% against 136.1%).
| Latest fiscal year | GSKGSK, 2025 | Novo Nordisk A SNVO, 2025 |
|---|---|---|
| Revenue | $43.09bn | $46.82bn |
| Revenue growth | 7.5% | 11.1% |
| Net income | $7.54bn | $15.52bn |
| Operating margin | 24.3% | 41.3% |
| Net margin | 17.5% | 33.1% |
| Return on equity | 38.5% | 61.6% |
| Free cash flow | $8.43bn | $8.93bn |
| Cash | $4.57bn | $4.16bn |
| Total debt | $23.83bn | $41.49bn |
| Debt to equity | 108.2% | 136.1% |
| Dividend per share | — | — |
| Dividend yield | — | 4.4% |
| Share buybacks | $1.82bn | $210m |
| Employees | — | — |
| Market value | $100.19bn | $177.65bn |
| Price vs our value range | Within our value range | Below our value range |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |